跳至主要内容
临床试验/NL-OMON32323
NL-OMON32323已完成不适用

Efficacy and safety of home treatment versus in hospital treatment with LMWH in patients with non-massive pulmonary embolism - The Hestia Study

GlaxoSmithKline0 个研究点目标入组 280 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Consecutive patients with proven acute non-massive, stable PE
  • 2. Age over 18
  • 3. Informed consent

排除标准

  • 1. Patients who have had symptoms of PE for longer than 7 days duration
  • 2. Diagnosis of PE during anticoagulant treatment
  • 3. Active bleeding, or a very high risk for major bleeding
  • 4. Severe pain requiring intravenous narcotic analgesia
  • 5. Medical or social condition which necessitates admission to the hospital for another reason
  • 6. Pregnancy
  • 7. Severe renal of liver failure
  • 8. Previously documented heparin induced thrombocytopenia

研究者

相似试验

Efficacy and safety of home treatment versus in... | 临床试验